TNGX - CIK 0001819133
Tango Therapeutics, Inc. (TNGX) reported revenue of $62.38M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Revenue | Change |
|---|---|---|
| FY 2025 | $62.38M | +48.3% |
| FY 2024 | $42.07M | +15.2% |
| FY 2023 | $36.53M | +46.9% |
| FY 2022 | $24.86M | -32.9% |
| FY 2021 | $37.04M | +383.8% |
| FY 2020 | $7.66M | - |
Tango Therapeutics, Inc. (TNGX) reported revenue of $62.38M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2020 and fiscal 2025, Tango Therapeutics, Inc.'s revenue grew from $7.66M to $62.38M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.